Drug Type Small molecule-drug conjugates |
Synonyms VYNFINIT, Vintafolide (USAN/INN) + [1] |
Target |
Mechanism FOLR1 agonists(Folate receptor alpha agonists), FOLR2 agonists(Folate receptor beta agonists), Tubulin modulators |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhasePhase 2 |
First Approval Date- |
RegulationOrphan Drug (US) |
Molecular FormulaC86H109N21O26S2 |
InChIKeyKUZYSQSABONDME-QRLOMCMNSA-N |
CAS Registry742092-03-1 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D10434 | Vintafolide |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Non-Small Cell Lung Cancer | Phase 2 | - | - | |
Advanced Triple-Negative Breast Carcinoma | Phase 1 | - | 01 Apr 2014 | |
Advanced cancer | Phase 1 | - | 01 Dec 2012 | |
Platinum-Resistant Ovarian Carcinoma | Phase 1 | - | 22 Apr 2011 | |
Non-small cell lung cancer stage IIIB | Phase 1 | - | 01 Mar 2011 | |
Solid tumor | Phase 1 | US | 31 Dec 2009 | |
Adenocarcinoma of Lung | Phase 1 | - | 01 Aug 2007 | |
Endometrial Carcinoma | Phase 1 | - | 01 Aug 2007 | |
Relapsed Solid Neoplasm | Phase 1 | US | 01 Mar 2006 | |
Ovarian Cancer | Preclinical | EU | - |
Phase 2 | 49 | idsjyhpreh(tkespuhbdz) = iqjfhwqvlr yuturuhtwn (jwoorgytjx ) | - | 01 Apr 2014 | |||
99mTc-etarfolatide | idsjyhpreh(tkespuhbdz) = yomrascjdn yuturuhtwn (jwoorgytjx ) | ||||||
Phase 2 | Platinum-Resistant Ovarian Carcinoma folate receptor | 149 | Vintafolide + PLD | (lakjkywjnw) = opwvrlpfdc vieqstpfyg (hexqxjbklk ) | Positive | 10 Dec 2013 | |
PLD alone | (lakjkywjnw) = ppwpmawbol vieqstpfyg (hexqxjbklk ) | ||||||
Phase 3 | 441 | Vintafolide + PLD | (cwxyyiijyh) = raosvzhggr kkaazpybrw (vsgzwfasdx ) | - | 20 May 2013 | ||
PLD + placebo | (cwxyyiijyh) = hlfrinbabr kkaazpybrw (vsgzwfasdx ) | ||||||
Phase 2 | 157 | Vintafolide+PLD | (ltexayfbrg) = tzxstvyobq mrcwnouhlg (hjxoafdcdu ) View more | - | 20 May 2013 | ||
PLD alone | (ltexayfbrg) = ndwwfffgnj mrcwnouhlg (hjxoafdcdu ) View more | ||||||
Phase 1 | Solid tumor FR-positive tumor xenografts | - | iemuannanh(lphjfkgemr) = Constipation was the dose-limiting toxicity with both routes hgaqwwhdrm (dmyinzappq ) View more | - | 10 Nov 2012 | ||
Phase 2 | 45 | (EC20++) | (rwvrterzej) = hnezzblpno ducxpzaxrj (xtnjufbcai ) View more | - | 20 May 2010 | ||
(EC20+) | (rwvrterzej) = hfgkomsrii ducxpzaxrj (xtnjufbcai ) View more | ||||||
Phase 1 | - | mwodvyurfi(eddbcscpre) = Constipation was the most common and clinically relevant toxicity induced by EC145 znzmsbrlmu (kubvpoyimg ) View more | - | 01 Dec 2009 |